Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial - The Lancet Oncology
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium - Annals of Oncology
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Metastatic Breast Cancer
BREAST CANCER - Daily Reporter
Abemaciclib plus aromatase inhibitor in advanced breast cancer
Breast cancer recurrence: factors impacting occurrence and survival | Irish Journal of Medical Science (1971 -)
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
Navigating HR+/HER2- Early Breast Cancer Treatment Strategies - Cancer Therapy Advisor
Rethinking neoadjuvant chemotherapy for breast cancer | The BMJ
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred | Scientific Reports
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Adjuvant chemotherapy plus endocrine therapy fails to increase OS in breast cancer subset
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older - Trevor Jolly, Grant R Williams, Ellen Jones, Hyman B Muss, 2012
Status of adjuvant endocrine therapy for breast cancer | Breast Cancer Research | Full Text
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
